MedTrace Logo

Resveratrol in Type2 Diabetes and Obesity

NCT01158417 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-11-09

No results posted yet for this study

Summary

The main objective of this study is to investigate the effect of resveratrol (plant derived food supplement) on inflammatory mediators and insulin resistance at the cellular and molecular level in obese non diabetic and type 2 diabetic subjects in vivo.

Conditions

Interventions

DRUG

Placebo

oral

DRUG

Resveratrol 40 mg oral three times a day

Drug

DRUG

Resveratrol 500 mg oral once daily.

Resveratrol 500 mg oral once daily.

Sponsors & Collaborators

  • Kaleida Health

    collaborator OTHER

  • University at Buffalo

    lead OTHER

Principal Investigators

  • Paresh Dandona, MD · Kaleida Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2012-07-08
Completion
2012-07-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01158417 on ClinicalTrials.gov